Ask AI
ProCE Banner Activity

From Overlooked to Identified: Bringing Tardive Dyskinesia Into Focus

Clinical Thought

Learn from an expert faculty in this commentary discussing etiology, prevalence, and patient burden of tardive dyskinesia in psychiatric settings. This overview of best clinical practices for screening, differential diagnosis, and FDA-approved treatment with VMAT2 inhibitors provides an introduction to our upcoming APP Intensive Workshop.

Released: May 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Teva.

Teva

Target Audience

This program is intended for nurse practitioners, nurses, physician assistants, and others involved in the care of patients with tardive dyskinesia who may benefit from this education.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement proactive risk-stratification and monitoring strategies to identify and counsel older adults or long-term antipsychotic-treated patients at heightened risk for TD

  • Apply validated screening tools and structured assessment protocols within routine clinical workflows to ensure timely detection, documentation, and follow-up of TD across diverse care settings

  • Evaluate the efficacy, safety, and tolerability profiles of FDA-approved VMAT2 inhibitors to individualize pharmacologic management of TD in older adults and special populations

Disclosure

Primary Author

Jeremy Schreiber, MSN, APRN, PMHNP-BC: consultant/advisor/speaker: Alkermes, Axsome, Biogen, Bristol Myers Squibb, Intra-Cellular, Janssen, Johnson & Johnson, Neurocrine, Sage, Supernus, Teva, Vanda; individual publicly traded stocks/stock options: Biogen, Bristol Myers Squibb, Sage.